MYCOF
Noveris Health Sciences Inc.·Healthcare
1.32
0.000%(+0.00)
Close PriceLast Updated: — ET
52W L: $0.0352W H: $1.40
MYCOF NEWS
thenewswire.com
Mar 26
Noveris Provides Announces Trading Halt Order, And Clarification As To Article
Vancouver, British Columbia, March 26, 2026 – TheNewswire – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces that the British Columbia Securities Commission (“ BCSC ”) issued an order dated March 25, 2026 under section 89(1) of the Securities Act (British Columbia) halting all trading in the Company's securities until April 16, 2026 (the “ Order ”) due to, among other matters, unexplained and unusual fluctuations in the volume of trading in, or market price, of the Company's shares traded on the CSE. The full text of the Order can be viewed on www.sedarplus.ca. The Company also wishes to clarify that the Company has not authorized, commissioned, or otherwise been involved in the creation or distribution of an article concerning the Company circulated by John Michaels on March 19, 2026 (the “ Article ”). The Company further confirms that neither the Company nor its investor relations service provider was aware of the Article prior to its publication, and neither has any relationship or affiliation with the individual or entities responsible for its authorship or dissemination. The Company did not provide information, commentary, review, approval, or input of any kind. Any statements, claims, or opinions expressed in the Article should not be construed as having been reviewed, verified, endorsed, or supported by the Company. In particular, the Article states that “the company is FDA-registered”. To the extent “FDA” refers to U.S. Food and Drug Administration, this statement is inaccurate. The Company does not have any registrations with the Food and Drug Administration, nor is actively pursuing any applications for registration for any of its products at this time. The Company refers readers to its public disclosure, which remains current, and confirms that it has no material undisclosed information at this time.
thenewswire.com
Mar 18
Noveris Announces Closing of Life Offering
Vancouver, British Columbia – TheNewswire - March 18, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has completed its previously announced non-brokered private placement and issued 9,625,049 units (each, a “ Unit ”) at a price of $0.24 per Unit for gross proceeds of $2,310,011.76 (the “ Offering ”). Each Unit consists of: (i) one common share of the Company and (ii) one common share purchase warrant, with each warrant entitling the holder thereof to acquire one additional common share of the Company at an exercise price of $0.30 for a period of 24 from the date of issuance.
thenewswire.com
Mar 16
Noveris Health Sciences Inc. Unaware Of Any Material Change
Vancouver, British Columbia, March 16, 2026 – TheNewswire - At the request of CIRO, Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. The Company is a biotechnology company focused on discovering and developing medications and therapies to address mental health disorders, including nicotine addiction and posttraumatic stress disorder (PTSD). The Company's objective is to use a blend of advanced technology with an elaborate infrastructure to speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions.
thenewswire.com
Mar 13
Noveris Health Sciences Launches Investor Website and Engages Fairfax Partners Inc. for Investor Relations and Digital Marketing Services
VANCOUVER, BC – TheNewswire - March 13, 202 6 – Noveris Health Sciences Inc. ( CSE: NVRS ) ( FSE: 0NF0 ) ( OTC: MYCOF ) (the " Company ") is pleased to announce the launch of its new investor-facing website at http://noveris.health . The website has been developed to provide shareholders, prospective investors, and other stakeholders with timely access to corporate information, investor materials, and company updates. The Company also announces that it has engaged Fairfax Partners Inc. ("Fairfax Partners"), headquartered in Vancouver, British Columbia, to provide investor relations management, communications infrastructure, and digital marketing services. The engagement for a total of up to CAD $150,000 plus applicable GST is effective March 13, 2026 and is for an initial term of three (3) months.
thenewswire.com
Mar 10
Noveris Announces Resignation Of CEO
Vancouver, British Columbia, March 10, 2026 – TheNewswire — Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today that Joshua Bartch has resigned as director, president and chief executive officer of the Company. The Company has appointed Jason Birmingham, who was previously appointed chief strategy officer on February 2, 2026, to assume all three positions formerly held by Mr. Bartch.
thenewswire.com
Mar 6
Noveris Announces Conversion Of Debentures; Filing Of Early Warning Reports By JJK Holdings Ltd. And Joshua Bartch
Vancouver, British Columbia, March 6, 2026 — TheNewswire - Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announces today the conversion of debentures in the aggregate principal amount of $8,188,628 (the “ Debentures ”) resulting in the issuance of a total of 47,687,939 common shares of the Company, initiated at the option of the debenture holders. The Debentures were originally issued by the Company on October 14, 2025. Based on their terms and conditions, the Debentures converted at a conversion price of $0.192682432, being the 20-day trailing volume-weighted average trading price of the Company's common shares as of the conversion date.
